ReviewInternational urogynecology journal2026
Comparative Efficacy and Safety of Nitrofurantoin Versus Fosfomycin for Acute Uncomplicated Lower Urinary Tract Infection: A Systematic Review and Meta-Analysis.
Review in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisNitrofurantoin and fosfomycin are first-line oral agents for acute uncomplicated lower urinary tract infection (u-UTI) in women, yet direct comparative evidence remains limited. This study compared clinical and microbiological outcomes of multi-day nitrofurantoin versus single-dose fosfomycin trometamol for u-UTI, including pregnant and nonpregnant women.
methodsDatabases were searched from inception through 9 May 2025, for RCTs comparing oral nitrofurantoin with single-dose fosfomycin trometamol (3g) for u-UTI. Primary outcomes were clinical and microbiological cure; secondary outcomes were 14-day relapse and adverse drug reactions (ADRs). Pooled risk ratios (RRs) with 95% CIs were calculated. Risk of bias was assessed using Cochrane RoB 2.0, and evidence certainty was graded using GRADE.
resultsSix RCTs (n = 1762; mean age 36.49±15.29) were included. Clinical cure at ≤7, 7-10, 14, and ≥28 days was comparable (RR 0.98, 0.99, 1.05, 1.02). Nitrofurantoin 300 mg/day was associated with higher clinical cure at 14 and ≥28 days (RR 1.14 and 1.22), whereas no significant difference was observed with 200 mg/day. In pregnant women, fosfomycin was associated with higher clinical cure at ≤7 days (RR 0.87; 95% CI 0.76-0.98). Microbiological cure showed no significant overall difference between treatments (RR 0.99; 95% CI 0.92-1.08), including at 14 and ≥28 days. Nitrofurantoin was associated with higher 14-day relapse (RR 1.71; 95% CI 1.13-2.59). Overall ADR rates were not significantly different (RR 1.27; 95% CI 0.95-1.70), although ADRs were higher with nitrofurantoin 300 mg/day (RR 1.63; 95% CI 1.07-2.49).
conclusionsNitrofurantoin and single-dose fosfomycin are both effective treatment options for uncomplicated cystitis. Treatment choice may be influenced by pregnancy, dosing regimen, and adherence considerations. Further well-designed trials are needed to clarify differences between treatment regimens.
Indexed as
Identifiers
42850453What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.